Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in tandem thanks to advancements in technology and a growing body of research on ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced it has exceeded its initial enrollment target for the stroke registrational program evaluating its Portable Neuromodulation Stimulator (PoNS® ...

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation sensor as 50% smaller than the G7, with a thinner, lower-circumference form ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Discover the potential of Ispire's innovative cannabis products and holistic solutions, a hidden gem in a competitive market with room to grow.

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.